Jean-Charles Soria, Head of Oncology Therapeutic Area at Amgen, posted on LinkedIn
“The oncology dealmaking landscape is shifting! Pharma is moving beyond niche drugs to focus on ADCs, bispecifics and radioligand therapies. Low interest in narrow biomarker drugs, pharma is chasing pan-cancer blockbusters!”
